This trial is open to women and men age 55 and older with active, relapsed or refractory acute myeloid leukemia (AML). Iomab-B is a drug that allows targeted delivery of the radiation dose directly to leukemic cells while limiting radiation exposure to normal organs that are not sites of disease. This treatment will be a way of reducing the disease without excessive toxicity prior to a hematopoietic stem cell transplant (HCT).
The primary objective of this study is to demonstrate the effectiveness of Iomab-B, in combination with a protocol-specific allogeneic HCT regimen, versus conventional care.
Subject will undergo screening prior to randomization into one of the following groups: